Dundee upgrades YM to “buy, venture risk”

Dundee Securities has upgraded YM BioSciences (TSX:YM; Amex:YMI) to “buy, venture risk” from “under review” based on the growing focus of JAK-1/2 inhibitors and the potential that may exist to differentiate YM’s CYT387 drug candidate in the space. Analyst David Martin writes that YM’s release of early data this week “suggests that CYT387 may provide [...]

Canaccord ups Theratechnologies on FDA approval

Canaccord Genuity has raised its price target on Theratechnologies (TSX:TH) to $7.85 from $7 after the FDA approved the company’s lead drug Egrifta for the treatment of HIV lipodystrophy, a metabolic disorder associated with HIV.  The stock closed at $5 on Wednesday. Analyst Neil Maruoka writes that he expects Egrifta to be launched in the [...]

GeneNews raises $2.1 Million

GeneNews (TSX: GEN) has accepted subscription agreements with a number of investors for two concurrent private placement offerings of units and convertible debentures to raise gross proceeds of $2,125,452, with insiders subscribing for about 49%. Each unit consists of one common share, one-half of a Series A warrant and one-half of a Series B warrant. [...]

Protected: Protox gets credibility boost from Warburg Pincus

There is no excerpt because this is a protected post.

Tekmira in 1-for-5 stock consolidation

Tekmira Pharmaceuticals (TSX:TKM) is consolidating its common stock on a one-for-five basis in order to meet listing requirements on the Nasdaq Stock Market, with the goal of listing on Nasdaq the week of Nov. 15, 2010. Tekmira will have 10,337,414 common shares outstanding after the consolidation. The stock will begin trading on a post-consolidated basis [...]

Helix closes private placement with Polish investor

Helix BioPharma (TSX,FSE:HBP; OTCQX:HXBPF) has closed a private placement of 4.53 million units at a price of $2.43 a unit with Polish investor Zbigniew Lobacz, who acquired the units for investments purposes. Net proceeds of about $9.5 million will be used for working capital, primarily to support the company’s clinical trials. Each unit consists of one [...]

Medicago in funding talks for U.S. vaccine plant

Medicago (TSX:MDG) has begun negotiating final terms and conditions with the U.S. Defense Advanced Research Projects Agency (DARPA) for a financing package to build a scalable plant to make plant-expressed, virus-like particles (VLP) vaccines. Medicago submitted its proposal for the plant in March, 2010.  ”Our proposal being selected by DARPA for potential funding demonstrates our [...]

AEterna to raise $12.1 million in direct offering

AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) has received commitments from institutional investors to purchase $12.1 million (U.S.) of securities in a registered direct offering under its U.S. shelf registration statement. The offering includes about 8.8 million common shares at a price of $1.3725 each and warrants to acquire about 4.4 million shares at an exercise price of [...]

Intellipharmaceutics files ANDA for generic Protonix

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has filed an ANDA with the FDA for a generic of Protonix (delayed-release pantoprazole sodium), which inhibits gastric acid secretion and is prescribed for conditions such as stomach ulcers associated with gastroesophageal reflux disease and hypersecretory conditions including Zollinger-Ellison syndrome. Sales of pantoprazole sodium delayed-release tablets in the U.S. were about [...]

Helix cream has no statistical significance for AGW

Helix BioPharma (TSX,FSE:HBP; OTCQX:HXBPF) has released results of a Phase 2 clinical trial of its topical interferon Alpha-2b cream for the treatment of ano-genital warts, which showed no statistically significant treatment effects between the treatment and the placebo groups. Topical interferon Alpha-2b was very well tolerated and there were no treatment-related serious adverse events, which is consistent [...]

« Previous Page — Next Page »